AS PER Invoice Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: AS PER Invoice Pharmaceutical Import Records from India — 3 Products, $194.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AS PER Invoice — Pharmaceutical Importer Profile (2026) | 3 Products, $194.2K Trade | TransData Nexus

AS PER Invoice

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $194.2K Total Trade · DGFT Verified

AS PER Invoice is a pharmaceutical importer based in Brazil with a total trade value of $194.2K across 3 products in 1 therapeutic categories. Based on 19 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. AS PER Invoice sources from 8 verified Indian suppliers, with Vama Lifecare Private Limited accounting for 81.1% of imports.

AS PER Invoice — Import Portfolio & Supplier Network

AS PER Invoice import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AS PER Invoice?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vama Lifecare Private Limited	$5.4M	2,594	81.1%
Vama Health World Llp	$804.2K	395	12.0%
Aspida Life Sciences Private Limited

What Formulations Does AS PER Invoice Import?

Formulation	Value	Ships
Harmless medicine for human consumption beractant intratracheal suspension 25MG ML 8ML batch number	$161.4K	6
Harmless medicine for human consumptiondorzolamide & timolol eye drops i.p. 5mlbatch no. 23195 mfg date.	$91.4K	3
Harmless medicine for human consumptiondorzolamide & timolol eye drops i.p. 5mlbatch no. 23196 mfg date.	$89.6K	3
Harmless medicine for human consumption trastuzumab deruxtecan 100 MG per vial batch number.: 418342	$60.2K	7
Harmless medicine for human consumptionbatch no g110g23a mfg dt: jul-23 exp dt:jun-28 as per	$50.0K	1
Harmless medicine for human consumptionbatch no g122j23a mfg dt:sep-23 exp dt:jul-28 as per	$50.0K	1
Harmless medicine for human consumptionbatch no g111g23a mfg dt: jul-23 exp dt: jun-28 as per	$50.0K	1
Harmless medicine for human consumptionnivolumab 100MG batch no. ack6323 mfgdt. 02/2023 exp dt.	$50.0K	1
Harmless medicine for human consumptionmelphalan powder for solu INJ/infusionbp50m/vial b/n:24cmp01 m/d:3/24	$50.0K	1
Harmless medicine for human consumptionisoflurane i.p 250 ML batch no g137k23amfg dt:oct-23 exp dt:aug-28 as per	$50.0K	1
Harmless medicine for human consumptionbatch number. 1241782 manufacturing date. 02/2024 expiry date. 07/2025	$50.0K	1
Harmless medicine for human consumption INJ. cetuximab 500 MG / 100 ML batch number.: g02htv manufacturing	$50.0K	1
Harmless medicine for human consumption INJ.beractant 25MG/ML,8ML batch number.: 1285571 manufacturing	$50.0K	1
Harmless medicine for human consumptionbatch no g32b25b mfg dt feb 25 exp dt jan 30 as per	$50.0K	1
Harmless medicine for human consumptionisoflurane i p 250 ML batch no g32b25b mfg dt feb 25 exp dt jan 30 isifrane	$50.0K	1

AS PER Invoice imports 2,880 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pembrolizumab	Advanced Oncology	$105.6K	10	5.5%	2
2	Nivolumab	Advanced Oncology	$72.9K	7	3.2%	3
3	Olaparib	Advanced Oncology	$15.6K	2	1.7%	7

AS PER Invoice imports 3 pharmaceutical products across 1 categories into Brazil totaling $194.2K.

AS PER Invoice — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AS PER Invoice is a pharmaceutical importer based in Brazil, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in 19 shipments from India, totaling an import value of $194,000 USD. Their product portfolio is entirely concentrated in the Advanced Oncology therapeutic category, with a focus on high-value oncology drugs. The top three imported products are Pembrolizumab ($106,000 USD), Nivolumab ($73,000 USD), and Olaparib ($16,000 USD), collectively accounting for 100% of their imports. This indicates a strategic emphasis on oncology treatments, likely driven by market demand and therapeutic needs in Brazil.

2Distribution Network

While specific details about AS PER Invoice's warehouse locations and logistics capabilities are not publicly available, their consistent import activity suggests a well-established distribution network within Brazil. The company's focus on high-value oncology drugs implies a need for specialized storage and handling facilities to maintain product integrity. Given the critical nature of these medications, AS PER Invoice likely collaborates with logistics partners experienced in pharmaceutical distribution to ensure timely and secure delivery to healthcare providers across the country.

3Industry Role

AS PER Invoice operates as a pharmaceutical importer, sourcing finished formulations from Indian manufacturers for distribution within Brazil. Their concentration on oncology drugs positions them as a specialized supplier catering to the needs of hospitals, clinics, and specialized pharmacies that require these high-cost, life-saving medications. By focusing on a niche segment, AS PER Invoice plays a crucial role in ensuring the availability of essential oncology treatments in the Brazilian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AS PER Invoice

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AS PER Invoice's sourcing strategy is highly concentrated, with 100% of their imports comprising the top three oncology drugs: Pembrolizumab, Nivolumab, and Olaparib. This singular focus on a limited product range suggests a strategic decision to specialize in high-demand oncology treatments, potentially allowing for better negotiation terms and streamlined logistics. However, this concentration also exposes the company to risks associated with supply chain disruptions, regulatory changes, or market fluctuations affecting these specific drugs. The absence of diversification in their product portfolio may limit their ability to adapt to shifts in market demand or therapeutic advancements.

2Supply Chain Resilience

The resilience of AS PER Invoice's supply chain is closely tied to their reliance on a single supplier, VAMA LIFECARE PRIVATE LIMITED, which accounts for 81.1% of their total imports. This dependency could pose challenges in the event of supply disruptions, such as production delays, quality issues, or geopolitical tensions affecting trade routes. To mitigate these risks, AS PER Invoice may consider diversifying their supplier base and establishing relationships with additional manufacturers. Additionally, ensuring compliance with Brazilian regulatory standards and maintaining robust quality assurance processes are essential to uphold the integrity of their supply chain.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical products is the Brazilian Health Regulatory Agency (ANVISA). ANVISA is responsible for the authorization of clinical trials, marketing authorization of drugs and biological products, and post-marketing surveillance. The regulatory framework for pharmaceutical imports is governed by Law No. 6,360/1976, which outlines the requirements for the importation, registration, and commercialization of pharmaceutical products. This law ensures that imported drugs meet the necessary safety, efficacy, and quality standards before they are made available to the Brazilian public.

2Import Licensing & GMP

Import licensing in Brazil requires that pharmaceutical products obtain prior approval from ANVISA through the Integrated System of Foreign Trade (SISCOMEX). This process involves submitting detailed documentation, including a commercial invoice, bill of lading, and certificate of origin. Additionally, ANVISA mandates that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. Certificates such as EU GMP, WHO GMP, or PIC/S are recognized by ANVISA and are essential for the registration and importation of pharmaceutical products into Brazil. Furthermore, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the country.

AS PER Invoice — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AS PER Invoice's product strategy focuses exclusively on the Advanced Oncology therapeutic category, importing high-value oncology drugs such as Pembrolizumab, Nivolumab, and Olaparib. This focus aligns with the growing demand for cancer treatments in Brazil, driven by an increasing incidence of cancer and a need for advanced therapeutic options. By specializing in this niche, AS PER Invoice can leverage expertise in oncology, build strong relationships with healthcare providers, and ensure a consistent supply of critical medications to the Brazilian market.

2Sourcing Profile

AS PER Invoice's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on oncology drugs. This approach allows the company to offer high-quality, cost-effective treatments to the Brazilian market. India's robust pharmaceutical manufacturing sector, known for its adherence to international GMP standards, makes it a reliable source for these products. By focusing on finished formulations, AS PER Invoice can streamline its operations and reduce the complexities associated with sourcing raw materials or active pharmaceutical ingredients.

3Market Positioning

Seller's Guide — How to Become a Supplier to AS PER Invoice

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with AS PER Invoice, particularly those offering high-quality oncology formulations that meet Brazilian regulatory standards. The existing gaps in AS PER Invoice's current sourcing strategy, such as the reliance on a single supplier, present opportunities for diversification and risk mitigation. By providing alternative sources for the same high-demand oncology drugs, new suppliers can help AS PER Invoice enhance supply chain resilience and ensure a consistent supply of critical medications to the Brazilian market.

2Requirements & Qualifications

Indian exporters seeking to supply AS PER Invoice and the Brazilian market must ensure that their products comply with ANVISA's regulatory requirements, including obtaining the necessary import licenses and adhering to GMP standards recognized by ANVISA. Products must undergo batch testing and stability studies to meet Brazilian quality standards. Labeling must be in Portuguese, providing detailed product information. Additionally, exporters should be prepared to provide all required documentation, such as commercial invoices, bills of lading, and certificates of origin, to facilitate the import process.

How to Approach

Frequently Asked Questions — AS PER Invoice

What products does AS PER Invoice import from India?

AS PER Invoice imports 3 pharmaceutical products across 1 categories. Top imports: Pembrolizumab ($105.6K), Nivolumab ($72.9K), Olaparib ($15.6K).

Who supplies pharmaceuticals to AS PER Invoice from India?

AS PER Invoice sources from 8 verified Indian suppliers. The primary supplier is Vama Lifecare Private Limited (81.1% of imports, $5.4M).

What is AS PER Invoice's total pharmaceutical import value?

AS PER Invoice's total pharmaceutical import value from India is $194.2K, based on 19 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AS PER Invoice focus on?

AS PER Invoice imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full AS PER Invoice Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.